Journal article
Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry
V Khou, JJ Anderson, G Strange, C Corrigan, N Collins, DS Celermajer, N Dwyer, J Feenstra, M Horrigan, D Keating, E Kotlyar, M Lavender, TJ McWilliams, P Steele, R Weintraub, H Whitford, K Whyte, TJ Williams, JP Wrobel, A Keogh Show all
Respirology | Published : 2020
DOI: 10.1111/resp.13768
Abstract
Background and objective: Early diagnosis of PAH is clinically challenging. Patterns of diagnostic delay in Australian and New Zealand PAH populations have not been explored in large-scale studies. We aimed to evaluate the magnitude, risk factors and survival impact of diagnostic delay in Australian and New Zealand PAH patients. Methods: A cohort study of PAH patients from the PHSANZ Registry diagnosed from 2004 to 2017 was performed. Diagnostic interval was the time from symptom onset to diagnostic right heart catheterization as recorded in the registry. Factors associated with diagnostic delay were analysed in a multivariate logistic regression model. Survival rates were compared across pa..
View full abstractGrants
Funding Acknowledgements
Funding for the registry was provided by Actelion, Allied Healthcare, Bayer, GlaxoSmithKline, Novartis and Pfizer via unrestricted grants to the PHSANZ. J.J.A. has received research support from GlaxoSmithKline and travel grants from Actelion and Bayer. G.S. reports grants from Actelion, Bayer, Pfizer Pharmaceuticals and GlaxoSmithKline, and personal fees from Actelion, Arena Pharmaceuticals, Bayer and GlaxoSmithKline outside the submitted work. N.C. has received research support and travel grants from Actelion. N.D. has received advisory payments from Actelion, GlaxoSmithKline and Bayer. M.H. has received research support from Actelion. D.K. has received speaking fees from GlaxoSmithKline, Actelion and Novartis. E.K. has received honoraria for speaking for Actelion, Bayer, Novartis, Servier and GlaxoSmithKline; has served on the advisory board for GlaxoSmithKline, Actelion and Bayer; and received research grants from GlaxoSmithKline and Actelion. M.L. has acted as a paid consultant to GlaxoSmithKline, Actelion and Bayer, and has received educational grants from GlaxoSmithKline, Actelion and Bayer. H.W. has received honoraria, speaker fees, travel grants and advisory board fees from Actelion, GlaxoSmithKline and Bayer. T.J.W. has served on scientific advisory boards of Actelion, GlaxoSmithKline and Bayer, and has received research and teaching support from Actelion. J.P.W. has received speaking fees, advisory board and travel grants from Actelion, Boehringer Ingelheim and Roche, and speaking fees and travel grants from GlaxoSmithKline. A.K. has served on advisory boards of Actelion, GlaxoSmithKline and Bayer, and participated in clinical trials sponsored by Actelion, Bayer, Pfizer, Gilead, Arena, Respira, Acceleron, Pfizer and Bellerophon. E.M.L. has received speaking and consultancy fees from Actelion and Menarini Pharmaceuticals, and has received research support from Actelion and GlaxoSmithKline.